Effects of hypertonic buffer composition on lymph node uptake and bioavailability of rituximab, after subcutaneous administration

Biopharmaceutics and Drug Disposition

Volumn 36, Issue 2, 2015, Pages 115-125

  Fathallah, Anas M ^a   Turner, Michael R ^a   Mager, Donald E ^a   Balu Iyer, Sathy V ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

biologics; lymphatic uptake; mannitol; O phospho L serine (OPLS); osmolarity

Indexed keywords

MANNITOL; PHOSPHOSERINE; RITUXIMAB; SODIUM CHLORIDE; BUFFER; HYPERTONIC SOLUTION; MONOCLONAL ANTIBODY; TROMETAMOL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG UPTAKE; ELIMINATION RATE CONSTANT; LYMPH NODE; MALE; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; SYSTEMIC CIRCULATION; ANIMAL; BIOAVAILABILITY; BLOOD; DRUG EFFECTS; METABOLISM; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BIOLOGICAL AVAILABILITY; BUFFERS; HYPERTONIC SOLUTIONS; INJECTIONS, SUBCUTANEOUS; LYMPH NODES; MALE; MANNITOL; MICE; PHOSPHOSERINE; RITUXIMAB; SODIUM CHLORIDE; TROMETHAMINE;

EID: 84924536481     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1925     Document Type: Article

References (30)

1. Swartz MA,. The physiology of the lymphatic system. Adv Drug Deliv Rev 2001; 50: 3-20. DOI: 10.1016/S0169-409X(01)00150-8
2. Richter WF, Bhansali SG, Morris ME,. Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J 2012; 14: 559-570.
3. Kagan L, Turner MR, Balu-Iyer SV, Mager DE,. Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. Pharm Res 2012; 29: 9.
4. Wang W, Wang EQ, Balthasar JP,. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 84: 548-558. doi: 10.1038/clpt.2008.170.
5. Deng R, Loyet KM, Lien S, et al., Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-α antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos 2010; 38: 600-605. doi: 10.1124/dmd.109.031310.
6. Deng R, Meng YG, Hoyte K, et al., Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice. MAbs 2012; 4: 101-109. doi: 10.4161/mabs.4.1.18543.
7. Porter CJ, Edwards GA, Charman SA,. Lymphatic transport of proteins after s.c. injection: implications of animal model selection. Adv Drug Deliv Rev 2001; 50: 157-171.
8. Bocci V, Muscettola M, Grasso G, Magyar Z, Naldini A, Szabo G,. The lymphatic route. 1. Albumin and hyaluronidase modify the normal distribution of interferon in lymph and plasma. Experientia 1986; 42: 432-433.
9. Bocci V, Muscettola M, Naldini A,. The lymphatic route. III. Pharmacokinetics of human natural interferon-beta injected with albumin as a retarder in rabbits. Gen Pharmacol 1986; 17: 445-448.
10. Yuan SYRR,. Structure and function of exchange. In Regulation of Endothelial Barrier Function. Morgan & Claypool Life Sciences: San Rafael, 2010.
11. Negrini D, Moriondo A,. Lymphatic anatomy and biomechanics. J Physiol 2011; 589: 2927-2934.
12. Schmid-Schonbein GW,. Microlymphatics and lymph flow. Physiol Rev 1990; 70: 987-1028.
13. Swabb EA, Wei J, Gullino PM,. Diffusion and convection in normal and neoplastic tissues. Cancer Res 1974; 34: 2814-2822.
14. Miclea RD, Purohit VS, Balu-Iyer SV,. O-Phospho-L-serine, multi-functional excipient for B domain deleted recombinant factor VIII. AAPS J 2007; 9: E251-E259. DOI: 10.1208/aapsj0902028 [doi]
15. Purohit VS, Ramani K, Sarkar R, Kazazian HH, Jr., Balasubramanian SV,. Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex. J Biol Chem 2005; 280: 17593-17600. DOI: M500163200 [pii] 10.1074/jbc.M500163200 [doi]
16. Fathallah AM, Ramakrishnan R, Balu-Iyer SV,. O-Phospho-L-serine mediates hyporesponsiveness towards FVIII in hemophilia A-murine model by inducing tolerogenic properties in dendritic cells. J Pharm Sci 2014; 103: 3457-3462.
17. Wu F, Tamhane M, Morris ME,. Pharmacokinetics, lymph node uptake, and mechanistic PK model of near-infrared dye-labeled bevacizumab after i.v. and s.c. administration in mice. AAPS J 2012; 14: 252-261. doi: 10.1208/s12248-012-9342-9.
18. Albert B, Johnson A, Lewis J,. Ion channels and the electrical properties of membranes. In Molecuar Biology of the Cell. Garland Science: New York, 2002.
19. Smiechowski M,. Theoretical pKa prediction of O-phosphoserine in aqueous solution. Chem Phys Lett 2010; 501: 123-129. DOI: 10.1016/j.cplett.2010.10.063
20. Randolph GJ,. Dendritic cell migration to lymph nodes: cytokines, chemokines, and lipid mediators. Semin Immunol 2001; 13: 267-274. doi: 10.1006/smim.2001.0322.
21. Oussoren C, Zuidema J, Crommelin DJ, Storm G,. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid compostion and lipid dose. Biochim Biophys Acta 1997; 1328: 261-272.
22. Margaris KN, Black RA,. Modelling the lymphatic system: challenges and opportunities. J R Soc Interface 2012; 9: 601-612.
23. Browse NL, Doig RL, Sizeland D,. The resistance of a lymph node to lymph flow. Br J Surg 1984; 71: 192-196.
24. Papp M, Makara GB, Hajtman B,. The resistance of in situ perfused lymph trunks and lymph nodes to flow. Experientia 1971; 27: 391-392.
25. Nony P, Girard P, Chabaud S, Hessel L, Thébault C, Boissel JP,. Impact of osmolality on burning sensations during and immediately after intramuscular injection of 0.5 ml of vaccine suspensions in healthy adults. Vaccine 2001; 19: 3645-3651. DOI: 10.1016/S0264-410X(01)00098-6
26. Momm J, Wallny HJ,. Antibody formulation. Google Patents, 2010.
27. Liu J, Shire SJ,. Reduced-viscosity concentrated protein formulations. Google Patents, 2002.
28. Immune globulin subcutaneous (human), 20% liquid. P T 2010; 35: 2-4.
29. Randolph GJ, Angeli V, Swartz MA,. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol 2005; 5: 617-628. DOI: nri1670 [pii] 10.1038/nri1670 [doi]
30. Fathallah AM, Bankert RB, Balu-Iyer SV,. Immunogenicity of subcutaneously administered therapeutic proteins-a mechanistic perspective. AAPS J 2013; 15: 897-900.